药品管理新规 构建全链条创新激励生态

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, 2026, optimizing the entire drug regulatory system and providing strong policy momentum for the innovative drug industry [1] Group 1: Drug Approval Process - The new regulations institutionalize and legalize the accelerated approval channels for breakthrough therapies, conditional approvals, priority reviews, and special approvals, which were first introduced in the 2020 "Drug Registration Management Measures" [1] - As of December 2025, 395 drug varieties have entered the breakthrough therapy program, 158 have been conditionally approved for market entry, and 508 have entered the priority review channel, with an average review time for innovative drugs shortened by 25% compared to 2018 [1] Group 2: Market Dynamics - The clarity of the regulatory framework is expected to encourage multinational companies to increase their investment in China, leading to more early-stage research and some companies choosing to conduct global research projects with China as the lead [2] - However, this trend may intensify market competition, putting pressure on domestic pharmaceutical companies to compete directly with top international firms, particularly affecting traditional Me-too and Me-better drugs [2] Group 3: Market Exclusivity - The new regulations introduce a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, provided that the drug supply is guaranteed [3] - This exclusivity is seen as a reasonable compensation for high-risk investments, potentially attracting more companies to invest in underdeveloped but essential areas [3] Group 4: Industry Transformation - The new regulations are expected to trigger profound changes in China's pharmaceutical industry, pushing domestic companies to upgrade and transform, shifting from low-level fast-follow strategies to high-level original innovation [4] - The competitive landscape is anticipated to evolve from local market competition to global market competition, driven by the need for companies to demonstrate real clinical value [4]